Galapagos NV
Below you will find information from the register publication of inside information. The information has been provided by the organisation.
Registration date
13 mar 2014 - 07:45
Statutory name
Galapagos NV
Title
Charles River Laboratories to acquire Galapagos' Argenta and BioFocus service operations for up to €134 million
Comments
Total cash consideration of up to €134 million
o €129 million cash payment
o earnout of €5 million upon achievement of revenue target after 12 months
· Proceeds to be used to progress Galapagos' pipeline
o four Phase 2 patient data readouts expected over next 15 months
o delivery of multiple Phase 1 studies and candidates in 2014
· Galapagos retains target discovery capabilities for its R&D and alliance operations
· Management guidance for 2014 Group revenues (including Argenta and BioFocus revenues Q1) of €125 million and year end cash of €170 million
Galapagos to hold a live audio webcast presentation today at 10.00 CET,
call number +32-2290-1608, www.glpg.com
Date last update: 02 May 2026